Market news

Agenus Inc. has surged >195% YTD, driven by optimism around its BOT/BAL combo therapy for MSS colon cancer. Read more on AGEN stock here.

Agenus (AGEN) shares were up nearly 13% in Monday afternoon trading after Chardan initiated coverage

U.S. stocks fell Monday, while Kodiak Sciences surged 174% after positive Phase 3 eye disease trial results; several small caps also rallied.

LEXINGTON, Mass., September 10, 2026--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that a poster evaluating botensilimab (BOT), an Fc-enhanced multifunctional anti-CTLA-4 antibody, in combination with balstilimab (BAL), an anti-PD-1 antibody, has been accepted for presentation at the International Gynecologic Cancer Society (IGCS) Annual Global Meeting, taking place October 1–3, 2026, in Montreal, Canada.

LEXINGTON, Mass., August 31, 2026--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that Robin Taylor, Ph.D., Chief Commercial Officer, and Zack Armen, Head of Corporate Development and Investor Relations, will participate in fireside chats and one-on-one investor meetings at two upcoming investor conferences in September.

LEXINGTON, Mass., August 28, 2026--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced the peer-reviewed publication of mature Phase 1b results from the fully enrolled C-800-01 cohort evaluating botensilimab (BOT), a multifunctional Fc-enhanced anti–CTLA-4 antibody, plus balstilimab (BAL), an anti–PD-1 antibody, in 123 heavily pre-treated patients with microsatellite-stable (MSS) metastatic colorectal cancer (mCRC) without active liver metastases.

LEXINGTON, Mass., August 26, 2026--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced the peer-reviewed publication of updated results from the investigator-sponsored Phase 2 NEST trial evaluating neoadjuvant botensilimab (BOT), Agenus’ multifunctional, Fc-enhanced anti-CTLA-4 antibody, and balstilimab (BAL), Agenus’ anti-PD-1 antibody, in patients with resectable colon cancer. The manuscript, titled "Neoadjuvant botensilimab/balstilimab for localized mismatch re

The latest analyst update on Agenus centers on a reset of its fair value estimate, with the price target moving from US$30.00 to US$19.50. This change reflects recent Street research that balances optimism about the refocused botensilimab and balstilimab pipeline with caution around financing plans and execution risks. As you read on, you will see how these shifting targets fit into the broader Agenus story and what to watch to keep up with the evolving narrative. Stay updated as the Fair...

LEXINGTON, Mass., August 06, 2026--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today reported financial results for the second quarter ended June 30, 2026, and provided an update on its financing-supported strategy to advance botensilimab (BOT), a multifunctional, Fc-enhanced anti-CTLA-4 antibody, plus balstilimab (BAL), an anti-PD-1 antibody, in a curative-intent treatment setting before surgery in high-risk, resectable microsatellite-stable (MSS) colon cancer.

Investors need to pay close attention to AGEN stock based on the movements in the options market lately.

LEXINGTON, Mass., July 17, 2026--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that three abstracts from investigator-sponsored trials evaluating botensilimab and balstilimab (BOT+BAL) have been accepted for poster presentation at the European Society for Medical Oncology (ESMO) Congress 2026, taking place October 23-27, 2026, in Madrid, Spain. The studies span neoadjuvant colorectal cancer, refractory metastatic colorectal cancer and advanced sarcoma, refle

Agenus (AGEN) is back in focus after reporting three year Phase 1b data for its BOT+BAL immunotherapy in refractory microsatellite stable metastatic colorectal cancer, alongside an oversubscribed private placement tied to its registrational ROBBIN trial. See our latest analysis for Agenus. The BOT+BAL data and oversubscribed financing come after a sharp shift in sentiment toward Agenus, with a 7 day share price return of 54.32% and a 30 day share price return of 67.79%, even as the 1 year...

Detailed price information for Novavax Inc (NVAX-Q) from The Globe and Mail including charting and trades.

Agenus is redirecting its Phase 3 colon-cancer strategy. The biotech company said on July 13 that it will stop providing financial support for its BATTMAN study and make ROBBIN, a planned Phase 3 trial of BOT+BAL before colon-cancer surgery, its central development priority. The shift is backed by ...

Earlier this month, Agenus released three-year landmark Phase 1b data showing that its botensilimab plus balstilimab combination produced clinically meaningful long-term survival and durable responses in heavily pretreated patients with refractory microsatellite-stable metastatic colorectal cancer without active liver metastases. An especially interesting finding was the plateau in the Kaplan-Meier survival curve beyond two years and the proportion of patients alive and off systemic...

Agenus (AGEN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

ORCL, VEEE, AGEN, MU, SNDK were among the stocks seen trending on Monday, July 13, 2026.

Gainers Agenus (NASDAQ:AGEN) shares increased by 95.8% to $6.56 during Monday's regular session. The market value of their outstanding shares is at $139.5 million. Q32 Bio (NASDAQ:QTTB) stock rose 81.08% to $20.3.

Agenus ($AGEN) stock rockets over 111% following stellar 3-year colorectal cancer data and a $340M financing deal.

Investing.com - U.S. stock futures were mixed on Monday as investors monitored a sharp selloff across the global memory-chip sector and assessed developments in the biotechnology space.

Agenus (Agenus Inc (NASDAQ:AGEN)) shares jumped about 100% on Monday after the biotechnology company announced an oversubscribed private placement of up to $340 million to support development of its botensilimab and balstilimab (BOT+BAL) immunotherapy combination in microsatellite-stable (MSS)...

Agenus (NASDAQ:AGEN) said it is shifting its development focus and financial resources toward a Phase 3 registrational trial of neoadjuvant botensilimab plus balstilimab, known as BOT/BAL, in high-risk stage 2 and stage 3 microsatellite stable colon cancer. Founder, Chairman and Chief Executive Off

LEXINGTON, Mass., July 13, 2026--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that it has entered into a securities purchase agreement for a private placement of approximately $85 million in upfront gross proceeds, before the deduction of private placement expenses, and up to an additional $255 million upon the full exercise of purchase warrants. The financing was led by Commodore Capital, with participation from RA Capital Management, TCGX, Invus, and Liga

Private Placement Strengthens Funding PositionAgenus Inc. (NASDAQ:AGEN) shares climbed 13% in premarket trading on Monday after the biotechnology company announced an $85 million private placement designed to strengthen its balance sheet and support the continued development of its clinical pipeline.

Agenus is financially abandoning an ongoing study in late-line colorectal cancer. Elsewhere, an ebola vaccine began human testing and an important Bristol Myers medicine got an FDA decision date.

LEXINGTON, Mass., July 06, 2026--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced three-year landmark Phase 1b data from the fully enrolled C-800-01 cohort evaluating botensilimab (BOT), an Fc-enhanced multifunctional anti–CTLA-4 antibody, plus balstilimab (BAL), an anti–PD-1 antibody, in patients with refractory microsatellite-stable (MSS) metastatic colorectal cancer (mCRC) without active liver metastases. The data were presented at the European Society for M